The Metabolism Assays Market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth in this market is attributed to the growing prevalence of diabetes, the global increase in the number of hospitals, and the high rate of obese population. However, alternative methods or techniques restrain the growth of this market.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=135163479
Market Dynamics
Drivers
- Increasing funding and investments in metabolic research
- Drug discovery and development
- Rise in prevalence of chronic diseases
- Increased use of metabolism assays in fitness and sports
- Growing demand for personalized medicines
Restraints
- High cost of metabolism assay analyzers
- Presence of alternative methods and techniques
Opportunities
- Integration with wearable devices
- Growing life science research in emerging economies
Challenges
- Complexity of assay development
Key Market Players
Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), Kaneka Eurogentec S.A. (Belgium), Sartorius AG (Germany), Promega Corporation (US), Elabscience Biotechnology Inc. (US), RayBiotech Life Inc. (US), BMG LABTECH (Germany), BIOTREND ChemiKalien GmbH (Germany), 3H Biomedical AB (Sweden), BioAssay Systems (US), EMELCA Bioscience (Netherlands), Creative Bioarray (US), Tempo Bioscience, Inc (US), Ncardia (Netherlands), NOVOCIB (France), Eton Bioscience Inc. (US), Cayman Chemical Company (US), Enzo Lifesciences, Inc. (US), and Abnova Corporation (Taiwan)
Thermo Fisher Scientific, Inc. (US)
Thermo Fisher is the leading player in the metabolism assays market. The company has a strong presence in North America, Europe, Asia Pacific, and Latin America, as well as numerous subsidiaries and distribution channels. Thermo Fisher’s strategic acquisition of PPD in December 2021 demonstrate the company’s commitment to expanding its portfolio and market presence. These acquisitions contribute to Thermo Fisher’s financial success and position the company as a leading player in the life science sector.
Merck KGaA (Germany)
Merck is the second leading player in the metabolism assays market. The company is globally present including Europe, North America, Asia Pacific, Latin America, the Middle East & Africa. Majorly, Merck focuses on external partnerships in its R&D operations, in-house research and maximizing research efficiency while reducing financial outlays. A solid foundation for the continued development of safe and cost-effective products has been provided by the Merck’s strong heritage of technology, leadership, and innovation.
Abcam Plc.
Abcam is a leading player in the global metabolism assays market. The company offers robust products. It has a wide geographic presence in North America, Europe, Asia Pacific, and the Middle East & Africa. Across the globe, Abcam has direct and indirect distribution network, which will protect the company’s business from building fluctuations in demand in various geographies.
North America dominates the global metabolism assay market.
Based on the region, the metabolism assay market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North American market is driven by well-established pharmaceutical and biotechnology industry, investments around drug discovery and toxicity testing. The Asia Pacific segment is projected to register the highest CAGR during the forecast period. The presence of a large population base coupled with large patient population and increasing rate of obesity are some of the major factors driving the growth of this regional market.
Recent Developments:
- In 2022, Thermo Fisher Scientific, Inc. (US) collaborated with Symphogen (Denmark) and Servier (France) for biopharmaceutical discovery and development laboratories.
- In 2021, Abcam Plc. (UK) acquired BioVision (UK). This acquisition of BioVision represents a compelling strategic fit for Abcam. This will bring greater control over the innovation and distribution of BioVision’s product portfolio and create value through portfolio expansion and leveraging Abcam’s global channels to market.
- In 2021, Agilent Technologies Inc. (US) launched Agilent Seahorse XF HS Miniplate which is the latest addition to Agilent’s range of Seahorse XF platforms, which analyze mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time.
Request 10% Customization:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=135163479
